Pembrolizumab (MK-3475) is a Humanized anti-PD-1 IgG4 Antibody for Cancer Research
Programmed death 1 (PD-1), also known as CD279, belongs to the CD28 superfamily. Firstly, PD-1 is an inhibitory receptor that is expressed on T cells, NK cells, B cells, monocytes, and dendritic cells. Secondly, PD-1 interacts with the ligands PD-L1 (B7-H1) and PD-L2 (B7-DC), which serves as a “rheostat”...
Glochidiol is an Orally Active Tubulin Polymerization Inhibitor for Lung Cancer Research
Tubulin is the protein that polymerizes into long chains or filaments that form microtubules, hollow fibers which serve as a skeletal system for living cells. Importantly, Tubulin includes α- and β-tubulin and polymerizes into dynamic microtubules. Particularly, Tubulin plays important roles in various cellular processes including spindle formation, apoptosis,...
Niraparib (MK-4827) is an Orally Active PARP1/PARP2 Inhibitor for Cancer Research
Poly (ADP-ribose) polymerases (PARPs) are a family of related enzymes that share the ability to catalyze the transfer of ADP-ribose to target proteins. There are at least 18 members of the PARP family. Some isoforms including PARP1 and PARP2 are best known for their involvement in DNA repair processes....
CFL-137 is a Potent KRasG12C Inhibitor for Lung Cancer Research
KRas (Kirsten rat sarcoma virus) is a part of the RAS/MAPK pathway and relays signals from outside the cell to the cell’s nucleus. Importantly, KRasG12C is a mutation of KRas. Moreover, KRasG12C also is an oncogenic driver mutation. Moreover, KRasG12C mutation has been considered potentially druggable by allele-specific direct...
Talazoparib (BMN-673) is an Orally Active PARP1/2 Inhibitor for Cancer Research
Breast cancer is the second most common cancer in the world. Although survival rates are constantly improving because of the current strategies of primary/secondary prevention and the availability of innovative and personalized therapeutic challenges, breast cancer is still the most frequent malignant neoplasia and the leading cause of cancer-related...
THK01 is a Potent ROCK2 Inhibitor for Breast Cancer Research
Breast cancer is the most common malignancy in women, and one of the three most common cancers worldwide, along with lung and colon cancer. Metastases from breast carcinoma are formed in various organs, especially the lung, bone, liver, and brain. In fact, lung metastasis is the primary cause of...
YL5084 is a Covalent JNK Inhibitor for Multiple Myeloma Research.
JNK is involved in regulating another mitochondrial protein cytochrome c during cell apoptosis. Specifically, Smac is the second mitochondrial-derived caspase activator, which promotes cell apoptosis by activating caspase. Without NF-κB In the case of activation, prolonged JNK activation contributes to TNF-α Induced cell apoptosis. Besides, JNK is also essential...